Chronic Pain - Pipeline Review - H1 2015





 
Date: February 2015

Description


Global Markets Direct’s, ‘Chronic Pain - Pipeline Review, H1 2015’, provides an overview of the Chronic Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
 
 

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 
 

 

 

 
 

 

Table of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Chronic Pain Overview 12
Therapeutics Development 13
Pipeline Products for Chronic Pain - Overview 13
Pipeline Products for Chronic Pain - Comparative Analysis 14
Chronic Pain - Therapeutics under Development by Companies 15
Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22
Chronic Pain - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Chronic Pain - Products under Development by Companies 27
Chronic Pain - Products under Investigation by Universities/Institutes 35
Chronic Pain - Companies Involved in Therapeutics Development 36
AbbVie Inc. 36
Acadia Pharmaceuticals Inc. 37
Adynxx, Inc. 38
Akron Molecules AG 39
Allergan, Inc. 40
arGEN-X BV 41
Astellas Pharma Inc. 42
Astraea Therapeutics, LLC 43
AstraZeneca PLC 44
BCN Peptides, S.A. 45
BioDelivery Sciences International, Inc. 46
Bionomics Limited 47
Cara Therapeutics, Inc. 48
ChironWells GmbH 49
Chromocell Corporation 50
Collegium Pharmaceutical, Inc. 51
CoLucid Pharmaceuticals, Inc. 52
Convergence Pharmaceuticals Ltd. 53
Creabilis SA 54
Cytogel Pharma, LLC 55
Daewoong Pharmaceutical Co., Ltd. 56
Daiichi Sankyo Company, Limited 57
Dompe Farmaceutici S.p.A. 58
DURECT Corporation 59
Egalet Corporation 60
Eli Lilly and Company 61
Endo Pharmaceuticals Inc. 62
Glenmark Pharmaceuticals Ltd. 63
Grunenthal GmbH 64
Johnson & Johnson 65
Kareus Therapeutics, SA 66
Kineta, Inc. 67
Kymab Limited 68
Laboratorios Del Dr. Esteve S.A. 69
Lohocla Research Corporation 70
Merck & Co., Inc. 71
Mertiva AB 72
Mesoblast Limited 73
Moberg Pharma AB 74
Mundipharma International Limited 75
Nanomerics Ltd 76
Nektar Therapeutics 77
Neura Therapeutik, LLC 78
Nippon Shinyaku Co., Ltd. 79
Orion Oyj 80
Pain Therapeutics, Inc. 81
Pfizer Inc. 82
Phosphagenics Limited 83
Purdue Pharma L.P. 84
Relmada Therapeutics, Inc. 85
Rottapharm SpA 86
Santen Pharmaceutical Co., Ltd. 87
Sea4Us 88
Shionogi & Co., Ltd. 89
Signature Therapeutics, Inc 90
Snowdon Inc. 91
Syntrix Biosystems, Inc. 92
Teikoku Pharma USA, Inc. 93
Teva Pharmaceutical Industries Limited 94
Trevena, Inc. 95
UMeWorld Limited 96
Zynerba Pharmaceuticals, Inc. 97
Chronic Pain - Therapeutics Assessment 98
Assessment by Monotherapy Products 98
Assessment by Combination Products 99
Assessment by Target 100
Assessment by Mechanism of Action 104
Assessment by Route of Administration 108
Assessment by Molecule Type 110
Drug Profiles 112
(celecoxib + tramadol hydrochloride) - Drug Profile 112
(oxycodone hydrochloride + naltrexone) ER - Drug Profile 113
A-836339 - Drug Profile 115
AAT-008 - Drug Profile 116
AGN-XX/YY - Drug Profile 117
AKR-201 - Drug Profile 118
APR-102 - Drug Profile 119
ARX-8203 - Drug Profile 120
ASP-7962 - Drug Profile 122
AXS-01 - Drug Profile 123
AXS-03 - Drug Profile 124
AYX-1 - Drug Profile 125
AYX-2 - Drug Profile 126
BBI-11008 - Drug Profile 127
bupivacaine hydrochloride - Drug Profile 128
buprenorphine hydrochloride - Drug Profile 130
buprenorphine hydrochloride depot - Drug Profile 132
buprenorphine hydrochloride ER - Drug Profile 133
cebranopadol - Drug Profile 134
celecoxib - Drug Profile 136
CNV-3000164 - Drug Profile 138
CNV-3000223 - Drug Profile 139
Conjugated Stigmine Program - Drug Profile 140
CR-701 - Drug Profile 141
CR-845 - Drug Profile 142
CRB-0022 - Drug Profile 144
CRB-0089 - Drug Profile 145
CT-340 - Drug Profile 146
Cyt-1010 - Drug Profile 147
DD-04107 - Drug Profile 149
dexmedetomidine hydrochloride - Drug Profile 150
DF-2593A - Drug Profile 152
Drugs for Chronic Pain and Inflammation - Drug Profile 153
Drugs for Chronic Pelvic Pain - Drug Profile 154
DS-1971 - Drug Profile 155
duloxetine hydrochloride DR - Drug Profile 156
DWJ-208 - Drug Profile 158
E-52862 - Drug Profile 159
Egalet-003 - Drug Profile 161
flurbiprofen - Drug Profile 162
FY-101C - Drug Profile 163
FY-103B - Drug Profile 164
GBR-900 - Drug Profile 165
Gene Therapy to Activate Endomorphin 2 for Chronic Pain - Drug Profile 166
Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 167
GIBH-1014 - Drug Profile 168
grapiprant - Drug Profile 169
HS-731 - Drug Profile 171
hydrocodone bitartrate - Drug Profile 172
hydrocodone bitartrate ER - Drug Profile 173
hydrocodone bitartrate ER - Drug Profile 175
hydrocodone bitartrate ER - Drug Profile 176
hydromorphone hydrochloride - Drug Profile 177
Kindolor - Drug Profile 178
KY-1017 - Drug Profile 180
LEVI-04 - Drug Profile 181
levorphanol tartrate ER - Drug Profile 182
lexanopadol - Drug Profile 183
mirogabalin - Drug Profile 184
Monoclonal Antibodies for Chronic Pain - Drug Profile 186
Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 187
morphine sulfate ER - Drug Profile 188
MPC-06ID - Drug Profile 189
NET-END - Drug Profile 191
NKTR-181 - Drug Profile 192
NL-001 - Drug Profile 194
NL-002 - Drug Profile 195
NM-0127 - Drug Profile 196
Omnitram - Drug Profile 197
onabotulinumtoxin A - Drug Profile 198
OSX-300 - Drug Profile 200
OSX-300 Backups - Drug Profile 201
oxycodone ER - Drug Profile 202
oxycodone hydrochloride ER - Drug Profile 204
oxycodone hydrochloride ER - Drug Profile 206
oxycodone hydrochloride ER - Drug Profile 207
oxycodone hydrochloride ER - Drug Profile 208
oxymorphone hydrochloride - Drug Profile 210
oxymorphone hydrochloride ER - Drug Profile 211
palmidrol - Drug Profile 212
Peptide to Block Calcium Channel for CNS Disorders - Drug Profile 213
Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 214
PF-05089771 - Drug Profile 215
PF-06372865 - Drug Profile 217
PF-329 - Drug Profile 218
PF-6129 - Drug Profile 219
PF-614 - Drug Profile 220
PFR-03088 - Drug Profile 221
PFR-03318 - Drug Profile 222
PFR-03321 - Drug Profile 223
PFR-03323 - Drug Profile 224
PFR-03325 - Drug Profile 225
PFR-06158 - Drug Profile 226
PFR-06177 - Drug Profile 227
PRC-062 - Drug Profile 228
Prostatic Acid Phosphatase - Drug Profile 229
PTI-202 - Drug Profile 230
PTI-721 - Drug Profile 232
SA-14867 - Drug Profile 233
Small Molecule Agonizing ER-Beta for Neurology and Pain - Drug Profile 234
Small Molecule for Central Nervous System - Drug Profile 235
Small Molecule for Chronic Pain - Drug Profile 237
Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 238
Small Molecule to Agonize mGlu2/3 for Chronic Pain - Drug Profile 239
Small Molecule to Antagonize TRPA1 for Chronic Pain - Drug Profile 240
Small Molecule to Block Cav2.2 Channel for Chronic Pain - Drug Profile 241
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 242
Small Molecule to Inhibit GPR-84 for Chronic Pain - Drug Profile 243
Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 244
Small Molecule to Inhibit P2Y14 for Chronic Pain - Drug Profile 245
Small Molecule to Modulate Ion Channel for Chronic Pain - Drug Profile 246
Small Molecules to Activate KCNQ Channels for Chronic Pain and CNS disorder - Drug Profile 247
Small Molecules to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 248
Small Molecules to Agonize NOP for Pain - Drug Profile 249
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Drug Profile 250
Small Molecules to Antagonize P2X3 for Chronic Pain - Drug Profile 251
Small Molecules to Antagonize Tyrosine Kinase Receptor A for Chronic Pain - Drug Profile 252
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 253
Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 254
Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 255
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 256
Small Molecules to Block Nav1.7 for Pain - Drug Profile 257
Small Molecules to Block TRPA1 and TRPV1 for CNS - Drug Profile 258
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 259
SND-121 Prodrug - Drug Profile 260
sufentanil citrate - Drug Profile 261
Synthetic Peptide to Inhibit CRMP-2 Protein for Pain - Drug Profile 263
tapentadol hydrochloride - Drug Profile 264
tramadol hydrochloride SR - Drug Profile 265
TROX-1 - Drug Profile 266
TRV-734 - Drug Profile 267
U-2902 - Drug Profile 268
UMB-425 - Drug Profile 269
V-116517 - Drug Profile 270
VLNX-4975 - Drug Profile 271
YYC-301 - Drug Profile 272
ZEP-3 - Drug Profile 273
ZYN-001 - Drug Profile 275
Chronic Pain - Recent Pipeline Updates 276
Chronic Pain - Dormant Projects 315
Chronic Pain - Discontinued Products 322
Chronic Pain - Product Development Milestones 324
Featured News & Press Releases 324
Appendix 333
Methodology 333
Coverage 333
Secondary Research 333
Primary Research 333
Expert Panel Validation 333
Contact Us 333
Disclaimer 334